A Study of Patients’ Preferences for Primary Immune Thrombocytopenia Treatment

by | Aug 25, 2026 | Clinical Trials | 0 comments

​ Conditions: Primary Immune Thrombocytopenia

Sponsors: Novartis Pharmaceuticals

Recruiting Conditions: Primary Immune Thrombocytopenia
Sponsors: Novartis Pharmaceuticals
Recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *